NLRP7

Across TCGA pan-cancer cohorts, NLRP7 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NLRP7 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher NLRP7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NLRP7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SKCM show a favorable association.

MESO, SCLC, and READ are the cancer types where NLRP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.055	0.573	<.001	42	view →
SCLC	DFS	Median	II,III,IV	0.178	0.611	.006	12	view →
READ	OS	Median	II,III,IV	0.172	0.673	.001	9	view →
BRCA	OS	Median	All	0.814	0.963	.015	9	view →
LUAD	DFS	Median	All	0.901	0.293	.013	4	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
SKCM	OS	Median	All	0.706	0.340	.018	3	view →
KIRP	OS	Median	All	0.320	0.716	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NLRP7–MESO (OS)

Open the MESO breakdown →